Multiple cellular origins and molecular evolution of intrahepatic cholangiocarcinoma
- PMID: 26940139
- DOI: 10.1016/j.canlet.2016.02.038
Multiple cellular origins and molecular evolution of intrahepatic cholangiocarcinoma
Abstract
Intrahepatic cholangiocarcinoma (ICC) is an aggressive malignancy associated with unfavorable prognosis and for which no effective treatments are available. Its molecular pathogenesis is poorly understood. Genome-wide sequencing and high-throughput technologies have provided critical insights into the molecular basis of ICC while sparking a heated debate on the cellular origin. Cancer exhibits variabilities in origin, progression and cell biology. Recent evidence suggests that ICC has multiple cellular origins, including differentiated hepatocytes; intrahepatic biliary epithelial cells (IBECs)/cholangiocytes; pluripotent stem cells, such as hepatic stem/progenitor cells (HPCs) and biliary tree stem/progenitor cells (BTSCs); and peribiliary gland (PBG). However, both somatic mutagenesis and epigenomic features are highly cell type-specific. Multiple cellular origins may have profoundly different genomic landscapes and key signaling pathways, driving phenotypic variation and thereby posing significant challenges to personalized medicine in terms of achieving the optimal drug response and patient outcome. Considering this information, we have summarized the latest experimental evidence and relevant literature to provide an up-to-date view of the cellular origin of ICC, which will contribute to establishment of a hierarchical model of carcinogenesis and allow for improvement of the anatomical-based classification of ICC. These new insights have important implications for both the diagnosis and treatment of ICC patients.
Keywords: Cellular origin; Heterogeneity; Intrahepatic cholangiocarcinoma; Pluripotent stem cells; Targeted therapy.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets.Expert Rev Gastroenterol Hepatol. 2017 Apr;11(4):349-356. doi: 10.1080/17474124.2017.1292127. Epub 2017 Feb 13. Expert Rev Gastroenterol Hepatol. 2017. PMID: 28162004
-
The Expression of Yes-Associated Protein (YAP) Maintains Putative Cancer Stemness and Is Associated with Poor Prognosis in Intrahepatic Cholangiocarcinoma.Am J Pathol. 2019 Sep;189(9):1863-1877. doi: 10.1016/j.ajpath.2019.05.014. Epub 2019 Jun 18. Am J Pathol. 2019. PMID: 31220448
-
Loss of ARID1A induces a stemness gene ALDH1A1 expression with histone acetylation in the malignant subtype of cholangiocarcinoma.Carcinogenesis. 2020 Jul 10;41(6):734-742. doi: 10.1093/carcin/bgz179. Carcinogenesis. 2020. PMID: 31665232
-
Cholangiocarcinoma: molecular pathways and therapeutic opportunities.Semin Liver Dis. 2014 Nov;34(4):456-64. doi: 10.1055/s-0034-1394144. Epub 2014 Nov 4. Semin Liver Dis. 2014. PMID: 25369307 Free PMC article. Review.
-
Cholangiocarcinoma: Classification, Histopathology and Molecular Carcinogenesis.Pathol Oncol Res. 2020 Jan;26(1):3-15. doi: 10.1007/s12253-018-0491-8. Epub 2018 Nov 17. Pathol Oncol Res. 2020. PMID: 30448973 Review.
Cited by
-
Efficacy and Safety of Apatinib Treatment for Patients with Advanced Intrahepatic Cholangiocarcinoma.Cancer Manag Res. 2020 Nov 10;12:11523-11526. doi: 10.2147/CMAR.S257526. eCollection 2020. Cancer Manag Res. 2020. PMID: 33204163 Free PMC article.
-
ALOX5 acts as a key role in regulating the immune microenvironment in intrahepatic cholangiocarcinoma, recruiting tumor-associated macrophages through PI3K pathway.J Transl Med. 2023 Dec 20;21(1):923. doi: 10.1186/s12967-023-04804-1. J Transl Med. 2023. PMID: 38124204 Free PMC article.
-
Lipid Metabolism Reprogramming in Tumor-Associated Macrophages Modulates Their Function in Primary Liver Cancers.Cancers (Basel). 2025 May 31;17(11):1858. doi: 10.3390/cancers17111858. Cancers (Basel). 2025. PMID: 40507339 Free PMC article. Review.
-
Differentiation of Hepatocellular Carcinoma from Intrahepatic Cholangiocarcinoma through MRI Radiomics.Cancers (Basel). 2023 Nov 11;15(22):5373. doi: 10.3390/cancers15225373. Cancers (Basel). 2023. PMID: 38001633 Free PMC article.
-
Translational Bioinformatics for Cholangiocarcinoma: Opportunities and Challenges.Int J Biol Sci. 2018 May 22;14(8):920-929. doi: 10.7150/ijbs.24622. eCollection 2018. Int J Biol Sci. 2018. PMID: 29989102 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases